Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc. filed a Form 8-K dated September 23, 2026. The company hosted a live webinar discussing its Open-Medicine AI multi-agentic artificial intelligence platform for drug development.
Financial and Operating Metrics
This filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. It is a Regulation FD disclosure regarding the webinar and related presentation.
Material Changes Versus Prior Period
The filing does not provide financial or operating comparisons with a prior period and does not disclose a material change in the company’s financial condition.
Guidance, Outlook, Risks, and Unusual Items
- A replay of the webinar is available through the provided YouTube link and the investor section of Lantern Pharma’s website.
- The presentation used during the webinar was furnished as Exhibit 99.1.
- The filing does not provide specific financial guidance, forecasts, risk updates, contingencies, or quantified development milestones.
- The Item 7.01 information and Exhibit 99.1 are furnished, not filed under Section 18 of the Exchange Act, and are not incorporated by reference into other filings unless expressly incorporated.
Key Facts for Investors to Verify
- Review the webinar replay and Exhibit 99.1 for details about the Open-Medicine AI platform, development capabilities, and any claims or forward-looking statements.
- Confirm whether the platform is associated with specific drug candidates, partnerships, timelines, or commercial opportunities not summarized in the Form 8-K text.
- Review subsequent SEC filings for financial results, funding needs, liquidity, clinical or preclinical progress, and updated risks.